taRgeting bEtA-Cell Function To achIeVe Remission of Type 2 diAbeTEs
The main objective of the REACTIVATE study is to investigate whether a period of intensive insulin therapy using closed-loop technology, when combined with diet and lifestyle education, can restore beta-cell function and achieve remission of recent-onset type 2 diabetes. This is a single-centre, open-label, randomised, parallel design study comparing up to 12 weeks of fully closed-loop insulin delivery to standard care with a glucose sensor in adults with recent-onset type 2 diabetes. The primary outcome is the…
Conditions studied
Type 2 Diabetes
About this study
The main objective of the REACTIVATE study is to investigate whether a period of intensive insulin therapy using closed-loop technology, when combined with diet and lifestyle education, can restore beta-cell function and achieve remission of recent-onset type 2 diabetes. This is a single-centre, open-label, randomised, parallel design study comparing up to 12 weeks of fully closed-loop insulin delivery to standard care with a glucose sensor in adults with recent-onset type 2 diabetes. The primary outcome is the number of participants achieving remission of diabetes at 52 weeks, defined as HbA1c below 48mmol/mol after 12 or more weeks off all diabetes medications. Other key outcomes include area under the curve for C-peptide and glucose during mixed meal tolerance test, the proportion of time spent with glucose levels within and above the target glucose range and mean sensor glucose as recorded by glucose sensor at 52 weeks. Safety evaluation comprises severe hypoglycaemic episodes, and other adverse and serious adverse events. Utility and human factors outcomes include glucose sensor and closed-loop usage, questionnaires and semi-structured interviews.
Interventions
- Device: Fully automated insulin delivery with CamAPS HX — Fully automated insulin delivery with CamAPS HX app, Libre 3 glucose sensor and Ypsopump insulin pump.
- Device: Standard diabetes therapy with a glucose sensor — Standard diabetes therapy with a Freestyle Libre 3 glucose sensor
Primary outcomes
- The number of participants achieving remission of diabetes at 52 weeks (52 weeks)
Eligibility information
Study locations
- Addenbrooke's Hospital NHS Foundation Trust, Cambridge, Cambridgeshire CB2 0QQ United Kingdom
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-19.